FDA wants to track social media talk about product risks; Google Glass could help prevent emerging health threats;

News From Around the Web

> The U.S. Food and Drug Administration wants to track social media talk about product risks, according to a solicitation notice posted to the Federal Business Opportunities site. "The objective of this requirement is to provide FDA with the resources needed to use social media to inform and evaluate FDA risk communications," the notice states. Notice

> Google Glass could help stop emerging public health threats around the world, according to recently published research in the journal ACS Nano. "It's very important to detect emerging public health threats early, before an epidemic arises and many lives are lost," study author Aydogan Ozcan, Ph.D., said. "With our app for Google Glass and our remote computing and data analysis power, we can deliver a one-two punch--provide quantified biomedical test results for individual patients, plus analyze all those data to determine whether an outbreak is imminent." Announcement

Health Insurance News

> Despite the success of Medicare's prescription drug program, changes proposed by the Obama administration are coming under heavy fire. Patient groups, pharmaceutical manufacturers and lawmakers in both parties are pushing back against changes the administrations says intend to help beneficiaries make good choices and save taxpayers money. Critics maintain there's no need to fix a program that isn't broken. Article

Health Provider News

> Clinical studies still overlook gender difference, which leave women at a disadvantage and could endanger their health, according to a new report from the Mary Horrigan Connors Center for Women's Health & Gender Biology at Brigham and Women's Hospital in Boston. Article

And Finally... Like a slap in the face! Article

Suggested Articles

The potential long-term impacts of COVID-19 on how Medicare Advantage's star ratings are calculated remain unclear, experts say.

There is a potential legal skirmish brewing between two of the largest telehealth companies over patent claims.

Buoyed by strong demand for its stock, GoodRx raised $1.1 billion in its IPO after pricing its deal well above its expected price range.